FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:496-498 February 3, 2005 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kaminski, M. S. PubMed Citation

Follicular lymphoma, one of the two most common lymphoid neoplasms in North America and Europe,¹ is diagnosed in approximately 15,000 adults in North America each year.² More than 90 percent of patients with this B-cell lymphoma have disseminated disease at diagnosis, and although the disease usually evolves slowly, most patients die of the lymphoma or complications of its treatment. Current treatments are effective in controlling the disease temporarily, often for years. The median overall survival from the time of diagnosis is approximately eight years, but survival is strongly influenced by age, the extent of disease, and the biology of the . . . [Full Text of this Article]

Source Information

From the British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.

This article has been cited by other articles:

• Buchegger, F., Press, O. W., Delaloye, A. B., Ketterer, N. (2008). Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma. The Oncologist 13: 657-667 [Abstract] [Full Text]  
• Knoops, L., Haas, R., de Kemp, S., Majoor, D., Broeks, A., Eldering, E., de Boer, J. P., Verheij, M., van Ostrom, C., de Vries, A., van't Veer, L., de Jong, D. (2007). In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 110: 1116-1122 [Abstract] [Full Text]  
• Sharkey, R. M., Goldenberg, D. M. (2006). Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. CA Cancer J Clin 56: 226-243 [Abstract] [Full Text]  
• Vallera, D. A., Brechbiel, M. W., Burns, L. J., Panoskaltsis-Mortari, A., Dusenbery, K. E., Clohisy, D. R., Vitetta, E. S. (2005). Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody. Clin. Cancer Res. 11: 7920-7928 [Abstract] [Full Text]  
• Lenz, G., Dreyling, M., Unterhalt, M., Hiddemann, W. (2005). In Reply:. JCO 23: 6264-6266 [Full Text]  
• Leonard, J. P. (2005). Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates. ASH Education Book 2005: 335-339 [Abstract] [Full Text]